G47.35
Congenital central alveolar hypoventilation syndrome
Clinical Classification Guidelines
Medical Intelligence & Overview
Congenital Central Alveolar Hypoventilation Syndrome (CCHS), also known as Congenital Central Hypoventilation Syndrome, is a rare neurological disorder present from birth that affects the regulation of breathing. People with this condition have difficulty automatically controlling their breathing, especially during sleep, which can lead to reduced oxygen levels and elevated carbon dioxide in the blood. The condition is linked to abnormal development of the brain regions responsible for control of breathing. Recognizing and managing CCHS is essential for maintaining good health and preventing complications.
Causes & Symptoms
Clinical Causes: Mutations in the PHOX2B gene, which plays a crucial role in the development of the autonomic nervous system responsible for involuntary functions like breathing. Genetic inheritance, often familial, though in some cases the cause may be a spontaneous genetic mutation. Disruption in the development of neural structures that regulate respiratory activity during fetal development and early life.
Key Symptoms: Difficulty breathing automatically, especially during sleep. Shallow breathing or periods of apnea (pauses in breathing). Reduced sensitivity to elevated carbon dioxide levels in the blood. Episodes of hypoxia—low oxygen saturation levels that may cause cyanosis (a bluish tint to the skin). Poor feeding and growth in infants with the disorder. Possible associated symptoms depending on severity, including autonomic dysregulation, such as abnormal heart rate, blood pressure fluctuations, or swallowing difficulties.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of CCHS involves a combination of clinical evaluation, genetic testing, and monitoring of breathing patterns. Key diagnostic steps include: - Clinical assessment of symptoms, especially during sleep. - Polysomnography (sleep study) to document abnormal breathing patterns. - Genetic testing to identify mutations in the PHOX2B gene. - Evaluation of autonomic functions and associated systems to determine the extent of nerve involvement. Accurate diagnosis is vital to initiate appropriate management strategies and prevent complications.
Treatment Protocols: Management of Congenital Central Alveolar Hypoventilation Syndrome focuses on supporting normal breathing and addressing related health issues. Treatment options include: - Mechanical ventilation, such as ventilators or tracheostomy, particularly during sleep, to ensure adequate oxygenation and ventilation. - Regular monitoring of blood oxygen and carbon dioxide levels. - Use of diaphragmatic pacing in some cases to stimulate breathing. - Management of associated autonomic dysfunctions and other neurological symptoms. - Multidisciplinary care involving pulmonologists, neurologists, and genetic counselors. - Supportive therapies, including nutritional support and minimization of complications. Advances in respiratory support technology and genetic understanding continue to improve the quality of life for individuals with CCHS.
Clinical Advice & FAQs
Billing Guidance
Is G47.35 a billable ICD-10 code?
Yes, G47.35 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G47.35?
Clinical documentation must specify the nature of Congenital central alveolar hypoventilation syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference